Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Point of Service Diabetes Screening Evaluation (POSSE)

This study has been completed.
Information provided by (Responsible Party):
VeraLight, Inc. Identifier:
First received: July 23, 2012
Last updated: January 13, 2013
Last verified: January 2013
The primary objective of the trial is to collect SCOUT DS, random capillary glucose and Hemoglobin A1c measurements from subject 18 years of age or older.

Diabetes Mellitus, Non-Insulin Dependent

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Point of Service Diabetes Screening Evaluation

Further study details as provided by VeraLight, Inc.:

Primary Outcome Measures:
  • To compare the accuracy of SCOUT DS versus random capillary glucose and several diabetes risk assessment questionnaires for detection of HbA1c-defined dysglycemia. [ Time Frame: one week ] [ Designated as safety issue: No ]

Enrollment: 667
Study Start Date: August 2012
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Detailed Description:
The objectives of this study are to compare the accuracy of SCOUT versus random capillary glucose and several diabetes risk assessment questionnaires for detection of HbA1C-defined dysglycemia.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Attendees of Blue Cross Blue Shield Wellness Event

Inclusion Criteria:

  • 18 years of age or older

Exclusion Criteria:

  • Known to be pregnant (self-reported)
  • Receiving dialysis or known renal compromise
  • Known to have photosensitivity
  • Taking medications that fluoresce
  • Have scars, any tattoos, rashes or other disruption/discoloration on the left volar forearm
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01669616

United States, Louisiana
Blue Cross Blue Shield of Louisiana
Baton Rouge, Louisiana, United States, 70809
Sponsors and Collaborators
VeraLight, Inc.
Principal Investigator: Andrea Barrack, MD Blue Cross Blue Shield of Louisiana
  More Information

Responsible Party: VeraLight, Inc. Identifier: NCT01669616     History of Changes
Other Study ID Numbers: VL-2723 
Study First Received: July 23, 2012
Last Updated: January 13, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by VeraLight, Inc.:
Type 2 Diabetes
Adults 18 years and older

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on December 08, 2016